Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Innovation Council · Finished

RondelO RondelO - the first medical stopcock designed for sequential intraveneous infusion of incompatible drugs

Coordinator
Cyto365 AB, Sweden
Runs
1 November 2022 to 30 April 2025
Status
Finished
EU funding
€1.9m
Total cost
€2.8m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190103560

What the project is doing

In the project's own words, from its summary on CORDIS.

CYTO365 is developing RondeO® - a revolutionary medical stopcock to be used with intravenous drug administration sets (IV sets). RondelO® is the first medical device that allows for a sequential intravenous administration of up to 6 drugs with the neutral saline in between the drugs. RondelO® aids the nurse to administer drugs to the patient safely and correctly, by letting only one drug pass at a time. It solves the problem of serious side effects caused by drug incompatibility by eliminating human error and unwanted parallel infusion and thereby increases patient safety.

Moreover, RondelO® is easy to use (minimal training required), safe for the user (Closed System Valve (CSV) minimizes hazardous drug expose for the nurse), customizable (different configurations with 2, 4 or 6 drug inlets with or without CSV available) and time-efficient (all drugs are connected to IV set at the beginning of the procedure).

Who is involved

OrganisationCityCountryRole
Cyto365 ABHoganasSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI